Adam Feuerstein Continues To Feel Ambivalent About Opexa
In an article on TheStreet, Adam Feuerstein said that he continues to have ambivalent feeling about Opexa Therapeutics (NASDAQ: OPXA). The company had reported disappointing phase IIb results of its experimental multiple sclerosis "vaccine" Tovaxin in September 2008. Ever since, OPXA has been regularly elaborating on this post-hoc analysis of the negative Tovaxin data with an aim to finding an iota of positive data.
OPXA has again announced the release of additional data from the phase II study of Tovaxin at the upcoming American Academy of Neurology (AAN) annual meeting. What remains to be seen is how different is the new data from the old one. Meanwhile, the company has not got around to fulfilling its promise of starting a new phase II study of Tovaxin in MS patients.
In response to a question from a reader, Adam Feuerstein clarified that under TheStreet.com’s conflict of interest policy, he is not allowed to own any individual stocks, nor can he short any stocks. He is also prohibited from investing in anything other than mutual funds. Moreover, he has been a business journalist long enough to avoid actions that can break his readers’ trust.
Read more from media.
